Results 101 to 110 of about 40,253 (233)

Analysis of the Matrix Metalloproteinases Family Profile in Gastric Cancer Suggests Key Matrix Metalloproteinases for Tumor Development and Their Clinical Impact

open access: yesMolecular Carcinogenesis, Volume 65, Issue 5, Page 577-588, May 2026.
ABSTRACT Gastric cancer (GC) is the fifth most common type worldwide, representing a public health problem. Among the genes related to this tumorigenesis, the family of matrix metalloproteinases (MMPs), essential regulators of the extracellular matrix (ECM), stand out for their involvement in the development and progression of GC.
Aline Costa Bastos   +11 more
wiley   +1 more source

Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]

open access: yes, 2019
Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph   +8 more
core   +2 more sources

Identifying the Initiation of a New Line of Therapy for Metastatic Lung, Breast, and Colorectal Cancer in Real‐World Data: A Scoping Review

open access: yesPharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose This study aimed to identify and synthesize published algorithms for identifying the initiation of a new line of therapy (LOT) for metastatic lung, breast, and colorectal cancer in real‐world data (RWD). Methods We conducted a scoping review of published, English‐language studies describing algorithms for identifying any LOTs with ...
Oluwadamilola Onasanya   +19 more
wiley   +1 more source

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

open access: yesJournal of Medical Case Reports, 2017
Background No standard chemotherapy regimen for advanced urothelial cancer has been established, except for cisplatin-based regimens. We report the case of a patient with double primary cancer, urothelial carcinoma of the upper urinary tract and ...
Takuya Tsujino   +12 more
doaj   +1 more source

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. [PDF]

open access: yes, 2007
We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver. Thirty-five patients enrolled in this multi-institutional phase I/II trial received up to eight arterial infusions ...
Au, T   +5 more
core  

Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure [PDF]

open access: yes, 2002
Background: The cytotoxic treatment of patients suffering from advanced or metastatic cancer undergoing hemodialysis due to chronic renal failure still remains a problem, since for those patients pharmacokinetic and pharmacodynamic data on most cytotoxic
Hacker, U.   +4 more
core   +1 more source

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

open access: yesCancer Science, Volume 117, Issue 5, Page 1422-1433, May 2026.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno   +6 more
wiley   +1 more source

Exosomal Non‐Coding RNAs in Gastrointestinal Cancer Drug Resistance: A Systematic Review of Emerging Mechanisms and Clinical Implications

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 9, May 2026.
ABSTRACT Gastrointestinal (GI) tumours are one of the most prevalent cancers globally. Even with normal GI function, individuals may develop neoplasms, highlighting the need to better understand the underlying causes of tumorigenesis. The emergence of tumour drug resistance represents the main reason for the failure of drug treatment; thus, it is ...
Mohsen Sharif‐zak   +6 more
wiley   +1 more source

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin

open access: yesCase Reports in Oncology, 2019
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous group of hematological malignancies involving T or NK cells. PTCLs are generally associated with an aggressive course and poor prognosis.
Koichi Kitazume   +4 more
doaj   +1 more source

Multidrug resistance of non-adherent cancer cells [PDF]

open access: yes, 2010
Metastases are the cause of 90% of human cancer deaths. Cancer in _situ_ can usually be effectively removed by surgery. Once cancer cells disseminate from the original site and start to circulate in blood, lymph, or other body fluids, the disease becomes
Guangming Liu   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy